Citi keeps a Buy rating on West Pharmaceutical (WST) with a $300 price target while adding an “upside 90-day short-term view.” The firm views West as one of the stronger margin stories in the space, and sees potential room for upside to consensus earnings estimates this year “when the temporary headwinds are in the rearview.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Hosts 2025 Shareholder Meeting
- West Pharma Faces Class Action Over Alleged Fraud
- West Pharmaceutical Services Earnings Call: Mixed Sentiments and Strategic Shifts
- West Pharmaceutical Services Reports Q1 2025 Earnings
- West Pharmaceutical Services: Strong Q1 Performance and Raised 2025 Guidance Justify Buy Rating